| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | C W Peterson | |
| H-P Kiem | |||
| K R Jerome | |||
| P Younan | |||
| P2860 | cites work | HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay | Q39155554 |
| The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment | Q39330860 | ||
| Gene repair of an Usher syndrome causing mutation by zinc-finger nuclease mediated homologous recombination. | Q39337792 | ||
| Frequency and stability of chromosomal integration of adenovirus vectors | Q39594975 | ||
| Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition | Q39638271 | ||
| HIV type-1 entry inhibitors with a new mode of action | Q39819133 | ||
| An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis | Q40651325 | ||
| CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis | Q41555285 | ||
| Prevalence of CCR5 Gene 32-Basepair Deletion in Populations of Slavic Origin. | Q42721377 | ||
| Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection | Q42744236 | ||
| Gene transfer into human cord blood-derived CD34(+) cells by adeno-associated viral vectors | Q43071787 | ||
| Integrase-independent HIV-1 infection is augmented under conditions of DNA damage and produces a viral reservoir | Q44473485 | ||
| Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding | Q44650819 | ||
| The binding mode of fusion inhibitor T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study | Q45831900 | ||
| TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages | Q45885683 | ||
| J2 prolongs the corneal allograft survival through inhibition of the CD4+ T cell-mediated response in vivo | Q46898352 | ||
| Latently infected cell activation: a way to reduce the size of the HIV reservoir? | Q47311740 | ||
| 32-nucleotide deletion, associated with defence against hiv/aids, is a predominant mutation of CCR5 gene in the population of Georgia. | Q54578397 | ||
| TNF-α levels are not increased in inflamed patients carrying the CCR5 deletion 32 | Q61927889 | ||
| Radiation-induced double strand breaks and subsequent apoptotic DNA fragmentation in human peripheral blood mononuclear cells | Q64386567 | ||
| Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34(+) peripheral blood progenitor cells | Q64387248 | ||
| Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2 | Q82971212 | ||
| Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry | Q83782523 | ||
| The 32-base pair deletion of the chemokine receptor 5 gene (CCR5-Delta32) is not associated with primary sclerosing cholangitis in 363 Scandinavian patients | Q83993234 | ||
| The geographic spread of the CCR5 Delta32 HIV-resistance allele | Q21146086 | ||
| Life expectancy of HIV-positive adults: a review | Q22248095 | ||
| TRIM5 is an innate immune sensor for the retrovirus capsid lattice | Q24300173 | ||
| How SAMHD1 changes our view of viral restriction | Q24605899 | ||
| Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs | Q24618983 | ||
| Targeted DNA mutagenesis for the cure of chronic viral infections | Q24620150 | ||
| Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells | Q24658337 | ||
| Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205 | Q24681004 | ||
| Novel approaches to inhibit HIV entry | Q27013957 | ||
| Hematopoietic-stem-cell-based gene therapy for HIV disease | Q27023434 | ||
| Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus | Q27664531 | ||
| Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells | Q28237048 | ||
| Cytoplasmic DNA innate immune pathways | Q28246926 | ||
| Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation | Q28300338 | ||
| Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy | Q28480578 | ||
| HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics | Q28481343 | ||
| The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract | Q28504884 | ||
| Intrinsic antiviral immunity | Q28709929 | ||
| Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery | Q29014419 | ||
| Genome Engineering With Zinc-Finger Nucleases | Q29301748 | ||
| Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu | Q29547836 | ||
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 | ||
| Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases | Q29615069 | ||
| Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases | Q29622846 | ||
| TAL effectors are remote controls for gene activation | Q30318498 | ||
| Hexagonal assembly of a restricting TRIM5alpha protein | Q30431451 | ||
| Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection | Q33514823 | ||
| Generation of human TRIM5alpha mutants with high HIV-1 restriction activity | Q33548284 | ||
| Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy | Q33622741 | ||
| Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation. | Q33783966 | ||
| Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody | Q33798442 | ||
| ZFNGenome: a comprehensive resource for locating zinc finger nuclease target sites in model organisms. | Q33806411 | ||
| The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin | Q36327928 | ||
| Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication | Q36330062 | ||
| Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study) | Q36376210 | ||
| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
| Modelling the impact of antiretroviral therapy on the epidemic of HIV | Q36486234 | ||
| The HIV-1 env protein: a coat of many colors | Q36856091 | ||
| The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association | Q36974663 | ||
| Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. | Q37207653 | ||
| Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability | Q37416925 | ||
| Adenovirus vector production and purification | Q37807438 | ||
| Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification | Q37827234 | ||
| Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years | Q37837963 | ||
| Targeting HIV: past, present and future | Q37853207 | ||
| Manufacturing of adenovirus vectors: production and purification of helper dependent adenovirus | Q37876776 | ||
| Host factors mediating HIV-1 replication | Q37922877 | ||
| Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients | Q37965592 | ||
| Antiretroviral therapy in treatment-naïve patients with HIV infection | Q37966740 | ||
| Neurocognitive dysfunction in the highly active antiretroviral therapy era. | Q37966773 | ||
| Oxidative stress and mitochondrial impairment after treatment with anti-HIV drugs: clinical implications | Q37970464 | ||
| Control of HIV latency by epigenetic and non-epigenetic mechanisms | Q37972643 | ||
| HIV-1 and hematopoietic stem cell transplantation. | Q37973860 | ||
| RNA-based therapeutics: current progress and future prospects. | Q37979387 | ||
| Molecular mechanisms of HIV entry | Q37980628 | ||
| Genome instability mechanisms and the structure of cancer genomes | Q37988292 | ||
| Eliminating the HIV reservoir | Q37993454 | ||
| CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects | Q38001046 | ||
| Lentiviral vectors: basic to translational | Q38002955 | ||
| APOBEC3G complexes decrease human immunodeficiency virus type 1 production | Q38286147 | ||
| Immune recovery and T cell subset analysis during effective treatment with maraviroc | Q38953936 | ||
| Decreased HIV diversity after allogeneic stem cell transplantation of an HIV-1 infected patient: a case report | Q39118296 | ||
| Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. | Q33822282 | ||
| Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. | Q33844698 | ||
| Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases | Q33886716 | ||
| p53 Gene repair with zinc finger nucleases optimised by yeast 1-hybrid and validated by Solexa sequencing | Q33939746 | ||
| Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery | Q33951767 | ||
| Adenosine-to-inosine RNA editing shapes transcriptome diversity in primates | Q33982232 | ||
| Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo | Q34124290 | ||
| Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1 | Q34132738 | ||
| Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity | Q34206875 | ||
| MHC class II tetramers | Q34258556 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| Issues to be considered when studying cancer in vitro | Q34348130 | ||
| Hematopoietic stem/precursor cells as HIV reservoirs. | Q34610023 | ||
| Adenovirus as an integrating vector | Q34729605 | ||
| Chemokine receptor 5 knockout strategies | Q34734219 | ||
| Signaling in thymic selection | Q34778134 | ||
| Ex vivo gene therapy for HIV-1 treatment | Q34982851 | ||
| R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies | Q35018129 | ||
| Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation | Q35077057 | ||
| Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication | Q35158133 | ||
| Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates | Q35568563 | ||
| The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines | Q35607320 | ||
| Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice | Q35623481 | ||
| Gene delivery to human and murine primitive hematopoietic stem and progenitor cells by AAV2 vectors | Q35670098 | ||
| TRAIL and malignant glioma. | Q35756919 | ||
| HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy | Q35766026 | ||
| The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies | Q35799529 | ||
| Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors. | Q35823895 | ||
| Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 va | Q35826525 | ||
| Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment | Q35876209 | ||
| Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. | Q35943417 | ||
| Initiation of DNA double strand break repair: signaling and single-stranded resection dictate the choice between homologous recombination, non-homologous end-joining and alternative end-joining | Q36003205 | ||
| Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. | Q36154128 | ||
| Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. | Q36155046 | ||
| P433 | issue | 7 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 695-702 | |
| P577 | publication date | 2013-01-31 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART | |
| P478 | volume | 20 |
| Q36028475 | A new hypothesis on HIV cure |
| Q33654409 | Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. |
| Q40150493 | Anti-proliferative therapy for HIV cure: a compound interest approach |
| Q35382218 | Antibody-free magnetic cell sorting of genetically modified primary human CD4+ T cells by one-step streptavidin affinity purification |
| Q38777005 | Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir |
| Q40448468 | Clinical Applications of Genome Editing to HIV Cure. |
| Q34475249 | Damaging the Integrated HIV Proviral DNA with TALENs |
| Q38777152 | Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach |
| Q36934918 | Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment |
| Q38260902 | Gene therapy for HIV infection. |
| Q38951248 | Gene transfer of two entry inhibitors protects CD4⁺ T cell from HIV-1 infection in humanized mice. |
| Q26995220 | Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? |
| Q34410446 | HIV cure research: advances and prospects |
| Q37021788 | HIV/AIDS eradication |
| Q42925261 | Hematopoietic cell transplantation and HIV cure: where we are and what next? |
| Q36920437 | Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates |
| Q36613666 | Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS |
| Q36195192 | Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus |
| Q39600778 | Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor |
| Q50878341 | Prospects for Foamy Viral Vector Anti-HIV Gene Therapy. |
| Q38314119 | Stem cell gene therapy for HIV: strategies to inhibit viral entry and replication |
Search more.